ProCE Banner Activity

How I Am Using PARP Inhibitors in the Care of Patients With Ovarian Cancer

Clinical Thought
Have you fully integrated the PARP inhibitors—olaparib, niraparib, and rucaparib—into your clinical practice in ovarian cancer? In this commentary, I discuss the importance of PARP inhibitors in ovarian cancer treatment and review considerations guiding their use.

Released: May 02, 2019

Expiration: April 30, 2020

Share

Faculty

Ursula Matulonis

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro

Faculty Disclosure

Primary Author

Ursula Matulonis, MD

Chief, Division of Gynecologic Oncology
Brock-Wilson Faculty Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ursula Matulonis, MD, has disclosed that she has received consulting fees from ImmunoGen, Merck, and Mersana.